146 related articles for article (PubMed ID: 8833222)
1. Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption.
Wei HM; Shah AJ; Tse J; Chi OZ; Weiss HR
Neurochem Res; 1996 Jan; 21(1):41-6. PubMed ID: 8833222
[TBL] [Abstract][Full Text] [Related]
2. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
Weiss HR; Rodriguez E; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
[TBL] [Abstract][Full Text] [Related]
3. Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Rabindranauth P; Scholz PM; Tse J; Naim KL; Weiss HR
Res Exp Med (Berl); 1998 Jul; 198(1):11-21. PubMed ID: 9706666
[TBL] [Abstract][Full Text] [Related]
4. Effects of topical methylene blue on cyclic GMP level, blood flow, and O2 consumption in focal cerebral ischaemia.
Wei HM; Tse J; Chi OZ; Weiss HR
Neurol Res; 1994 Dec; 16(6):449-55. PubMed ID: 7708136
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitroprusside on regional cerebral cyclic GMP, blood flow and O2 consumption in rat.
Lu X; Wei HM; Yospin J; Weiss HR
Brain Res; 1995 Jan; 669(1):35-40. PubMed ID: 7712162
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.
Trapani AJ; Smits GJ; McGraw DE; McMahon EG; Blaine EH
J Pharmacol Exp Ther; 1991 Jul; 258(1):269-74. PubMed ID: 1649294
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle.
Chilvers ER; Giembycz MA; Challiss RA; Barnes BJ; Nahorski SR
Br J Pharmacol; 1991 May; 103(1):1119-25. PubMed ID: 1652339
[TBL] [Abstract][Full Text] [Related]
8. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
[TBL] [Abstract][Full Text] [Related]
9. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
10. Zaprinast accelerates recovery from established acute renal failure in the rat.
Guan Z; Miller SB; Greenwald JE
Kidney Int; 1995 Jun; 47(6):1569-75. PubMed ID: 7643525
[TBL] [Abstract][Full Text] [Related]
11. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Thusu KG; Morin FC; Russell JA; Steinhorn RH
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
[TBL] [Abstract][Full Text] [Related]
12. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats.
Dundore RL; Clas DM; Wheeler LT; Habeeb PG; Bode DC; Buchholz RA; Silver PJ; Pagani ED
Eur J Pharmacol; 1993 Nov; 249(3):293-7. PubMed ID: 8287916
[TBL] [Abstract][Full Text] [Related]
13. Effects of zaprinast on renal nerve stimulation-induced anti-natriuresis in anaesthetized dogs.
Sekizawa T; Shima Y; Yoshida K; Tanahashi M; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
Clin Exp Pharmacol Physiol; 1998 Dec; 25(12):1008-12. PubMed ID: 9887998
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes.
Zhang S; Rodriguez R; Scholz PM; Weiss HR
Pharmacology; 2006; 76(2):53-60. PubMed ID: 16276122
[TBL] [Abstract][Full Text] [Related]
15. Lack of the nitric oxide-cyclic GMP-potassium channel pathway for the antinociceptive effect of intrathecal zaprinast in a rat formalin test.
Yoon MH; Choi JI; Bae HB; Jeong SW; Chung SS; Yoo KY; Jeong CY; Kim SJ; Chung ST; Kim CM
Neurosci Lett; 2005 Dec; 390(2):114-7. PubMed ID: 16115733
[TBL] [Abstract][Full Text] [Related]
16. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide.
Weisbrod RM; Griswold MC; Yaghoubi M; Komalavilas P; Lincoln TM; Cohen RA
Br J Pharmacol; 1998 Dec; 125(8):1695-707. PubMed ID: 9886761
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain.
Gao F; Sugita M; Nukui H
Neurol Res; 2005 Sep; 27(6):638-43. PubMed ID: 16157016
[TBL] [Abstract][Full Text] [Related]
18. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
Kruuse C; Rybalkin SD; Khurana TS; Jansen-Olesen I; Olesen J; Edvinsson L
Eur J Pharmacol; 2001 May; 420(1):55-65. PubMed ID: 11412839
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.
Weyerbrock A; Walbridge S; Saavedra JE; Keefer LK; Oldfield EH
Neuro Oncol; 2011 Feb; 13(2):203-11. PubMed ID: 21041233
[TBL] [Abstract][Full Text] [Related]
20. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors.
Sugita M; Black KL
Cancer Res; 1998 Mar; 58(5):914-20. PubMed ID: 9500450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
